뉴스&공지

뉴스

GENIXCURE-ToolGen, Joint R&D contract for treatment of progeria

2022-12-20

GENIXCURE-ToolGen, Joint R&D contract for treatment of progeria


 

▲ Kim Young-ho, CEO of ToolGen (left), and Moon Hong-sung, CEO of GENIXCURE


ToolGen gene editing platform utilizes AAV technology from GENIXCURE


ToolGen announced on the 20th that it has signed a joint research and development agreement with ANL BIO to develop progeria gene therapy.


View the original article




Yoon So-young, a bio-speculator

soyoung.yoon@bios.co.kr